What are the guidelines for patent ductus arteriosus (PDA) closure in children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

PDA Closure in Children: Guideline-Based Recommendations

Primary Treatment Approach

Transcatheter device closure is the first-line intervention for PDA closure in children and should be prioritized over surgical approaches whenever technically feasible. 1, 2, 3


Indications for PDA Closure

Class I (Definitive) Indications

Closure is mandatory when any of the following are present:

  • Left atrial or left ventricular enlargement attributable to PDA with net left-to-right shunt 1, 3
  • Congestive heart failure or failure to thrive 1, 3
  • Pulmonary overcirculation (with or without pulmonary hypertension) 1
  • Pulmonary artery systolic pressure <50% of systemic pressure AND pulmonary vascular resistance <1/3 systemic 1

Class IIa (Reasonable) Indications

Closure is reasonable for:

  • Small PDA with continuous murmur audible by standard auscultation, even if asymptomatic with normal-sized heart chambers 1, 3

Class IIb (May Consider) Indications

Closure may be considered in rare instances:

  • Bidirectional PDA shunt with pulmonary hypertension that is reversible to pure left-to-right shunting with pulmonary vasodilator therapy 1
  • PA systolic pressure ≥50% systemic and/or pulmonary vascular resistance >1/3 systemic, but only if net left-to-right shunt persists 1

Class III (Contraindicated)

Closure is contraindicated when:

  • Net right-to-left shunt (Eisenmenger physiology) with PA systolic pressure >2/3 systemic or pulmonary vascular resistance >2/3 systemic 1, 3

Device Selection and Technical Approach

Preferred Devices

  • Amplatzer Duct Occluder: Standard device for PDAs up to 16 mm, with 99.7% complete occlusion at 1-year follow-up 1
  • Coil devices: Multiple coil techniques for smaller PDAs 1, 4
  • Amplatzer Muscular VSD Occluder: For tubular (type C) PDAs in small children with congestive heart failure, particularly when standard PDA devices fail 5

Technical Considerations

  • Minimum weight: While manufacturer recommendations exclude patients <6 kg, successful closure has been reported in infants as small as 2.4-2.5 kg, though technically more challenging 1, 5
  • Anticoagulation: Administer 50-100 U/kg unfractionated heparin at time of device implantation 3

Critical Pre-Procedural Assessment

Mandatory Evaluations

Before any closure attempt, perform:

  1. Differential oxygen saturation measurement in both feet AND both hands to detect right-to-left shunting 1, 2
  2. Echocardiography with color Doppler in parasternal short-axis view to confirm diagnosis 3, 6
  3. Continuous-wave Doppler to measure transpulmonary gradient and estimate PA pressure 3

When Cardiac Catheterization is Required

Proceed to invasive hemodynamic assessment when: 3, 6

  • Significant elevation of pulmonary vascular resistance is suspected
  • Echocardiography is non-diagnostic
  • Assessment of shunt direction, PVR, and pulmonary vascular bed reactivity is needed
  • Pulmonary vasoreactivity testing is mandatory before considering closure in patients with bidirectional flow 1

Surgical Closure: Reserved Scenarios Only

Surgery should only be considered when: 2, 3

  • PDA is too large for device closure
  • Distorted ductal anatomy precludes device placement
  • Calcified PDA (particularly in adults)
  • Concomitant cardiac surgery is required for other indications

Critical caveat: Consult with ACHD interventional cardiologists before selecting surgical closure, especially for calcified PDAs 3


Special Population: Pulmonary Hypertension

Children with Elevated PA Pressures

  • Transcatheter closure can be performed safely in children with pulmonary hypertension (PVRI >3 WU·m²) if net left-to-right shunt persists 7
  • 72.7% of patients on pulmonary vasodilators pre-closure were successfully weaned post-procedure (median 24 months) 7
  • Premature infants with pulmonary hypertension particularly benefit from closure 7

Risk Stratification

  • Higher complication risk: Coil devices in hypertensive PDAs (avoid if possible) 7
  • ICU admission more likely: Patients on baseline pulmonary vasodilator therapy (83.3% vs 14.3%) 7

Post-Closure Management

Endocarditis Prophylaxis

  • Discontinue 6 months after complete closure is documented 2
  • Continue prophylaxis if residual shunt persists 1

Follow-Up Schedule

  • Serial echocardiograms to monitor for complete closure 3
  • Discharge from follow-up once complete closure documented by echocardiography 1, 2, 3
  • For small PDAs without left-heart volume overload: routine follow-up every 3-5 years 3
  • For device closure patients: follow-up every 5 years due to limited long-term data 2

Expected Outcomes

  • Complete occlusion rates: 77.8% at 24 hours, 92.6% at 1 month, 94.4% at long-term follow-up 4
  • Residual shunting through Amplatzer devices is common initially but resolves in 99.7% by 1 year 1

Complications and Management

Device-Related Complications (Rare)

  • Device embolization: 9.1% in one series, more common with coils 7
  • Aortic obstruction (iatrogenic coarctation) in small infants 1
  • Left pulmonary artery stenosis: Mild stenosis may occur but typically improves over time 5
  • Hemolysis and recanalization: Rare 1

Prevention Strategies

  • Careful ductal and ampulla measurements for device selection 1
  • Post-implantation evaluation before device release 1
  • Avoid coil devices in hypertensive PDAs 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Patent Ductus Arteriosus Closure Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Patent Ductus Arteriosus Management in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Percutaneous treatment of moderate-to-large patent ductus arteriosus with different devices: early and mid-term results.

Italian heart journal : official journal of the Italian Federation of Cardiology, 2005

Guideline

Patent Ductus Arteriosus Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.